Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIMUM: Pregabalin and Alpha-Lipoic Acid in Diabetic Peripheral Neuropathy
NCT04846673Phase 4Completed
- Sponsor
- Yuhan
- Start
- May 2021
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of pregabalin, alpha-lipoic acid in diabetic peripheral neuropathy (DPN), sponsored by Yuhan. Started May 2021; status: completed.
02
Drugs
pregabalinalpha-lipoic acid
03
Conditions
diabetic peripheral neuropathy (DPN)
Beyond the preview
Go deeper on NCT04846673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04846673.